IP Library Granted Patent US 8,802,385
Granted Patent B2
US 8,802,385 · App. 11/766,934 · Granted Aug 12, 2014

Suspension medium for red blood cells comprising amino acids

Inventors: Daniel Martorell Pena (Barcelona, ES); Ma del Carmen Traves Polo (Barcelona, ES); Jordi Farre Leon (Barcelona, ES); Josefina Castells Parera (Barcelona, ES)
Assignee: Grifols, S.A.
G01N33/80G01N33/96
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,802,385
App. No.
11/766,934
Granted
Aug 12, 2014
Kind
B2
Abstract

The present invention relates to a new suspension medium or diluent solution for red blood cells for use in haematological methods. The suspension medium or diluent solution for red blood cells may comprise a combination of two or more amino acids of any group, and preserves the red blood cells in the sample for at least 8 weeks.

Claims (13)

1. A suspension medium or diluent solution for reagent red blood cells, comprising phosphate buffer, sodium chloride, glucose, adenine, at least one preservative, EDTA and glycine and a combination of two or more amino acids of any group, wherein the amino acids other than glycine are present in a concentration of 0.50 to 6.48 g/l resulting in a total osmolality of between about 100-700 milliosmol/kg for the suspension medium or diluent solution and the combination of two or more amino acids other than glycine in the suspension medium or diluent solution reduces the loss of specificity and non-specific retention of the reagent red blood cells, and maintains the integrity and functionality of the reagent blood cells.

2. The suspension medium or diluent solution for reagent red blood cells according to claims 1 further comprising inosine, citrate, citric acid and bicarbonate.

3. The suspension medium or diluent solution for reagent red blood cells according to claim 1 , wherein the combination of two or more amino acids comprises a combination of aliphatic amino acids.

4. The suspension medium or diluent solution for reagent red blood cells according to claim 3 , wherein the combination of aliphatic amino acids is selected from the group consisting of: L-alanine, L-valine, L-leucine and L-isoleucine.

5. The suspension medium or diluent solution for reagent red blood cells according to claim 1 , wherein the combination of two or more amino acids is selected from the group consisting of aliphatic amino acids, aromatic amino acids and amino acids which contain sulphur.

6. The suspension medium or diluent solution for reagent red blood cells according to claim 5 , wherein the combination comprises a combination of aliphatic amino acids and amino acids selected from the group consisting of: L-phenylalanine, L-tyrosine, L-tryptophan, L-methionine and L-cysteine.

7. The suspension medium or diluent solution for reagent red blood cells according to claim 1 , wherein the combination of two or more amino acids comprises: L-valine, L-methionine, L-leucine, and L-isoleucine.

8. The suspension medium or diluent solution for reagent red blood cells according to claim 1 , wherein the combination of two or more amino acids comprises a combination of hydrophobic and hydrophilic amino acids.

9. The suspension medium or diluent solution for reagent red blood cells according to claim 1 , wherein the combination of two or more amino acids comprises a combination of aliphatic amino acids and amino acids selected from the group consisting of chargeless, positively charged and negatively charged polar amino acids.

10. The suspension medium or diluent solution for reagent red blood cells according to claim 9 , wherein the combination of two or more amino acids comprises a combination of aliphatic amino acids and of the amino acids: L-serine, L-threonine, L-cysteine, L-methionine, L-asparagine, L-glutamine, L-lysine, L-arginine, L-histidine, L-aspartic acid and L-glutamic acid.

11. The suspension medium or diluent solution for reagent red blood cells according to claim 1 , wherein the combination of two or more amino acids comprises a combination of aliphatic amino acids, and of polar, neutral or charged amino acids (positive and/or negative), and aromatic amino acids.

12. The suspension medium or diluent solution for reagent red blood cells according to claim 1 , wherein the combination of two or more amino acids comprises a combination of non-polar and polar amino acids.

13. A method for preserving red blood cells comprising mixing a red blood cell sample in the suspension medium or diluent solution of claim 1 , thereby preserving the red blood cells in the sample as a hematological reagent for at least 8 weeks.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Feb 6, 2017
From: DEUTSCHE BANK AG NEW YORK BRANK
To: GRIFOLS THERAPEUTICS INC.; GRIFOLS SHARED SERVICES NORTH AMERICA INC.; GRIFOLS DIAGNOSTIC SOLUTIONS INC.
Reel/Frame 041638/0527 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 26390/0193 Recorded Jan 25, 2017
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: GRIFOLS, S.A.; GRIFOLS INC.; TALECRIS BIOTHERAPEUTICS, INC.
Reel/Frame 041494/0017 →
SECURITY AGREEMENT Recorded Feb 27, 2014
From: GRIFOLS INC.; GRIFOLS THERAPEUTICS INC.; GRIFOLS-CHIRON DIAGNOSTICS CORP.
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 032367/0001 →
SECURITY AGREEMENT Recorded Jun 3, 2011
From: GRIFOLS, S.A.; GRIFOLS INC.; TALECRIS BIOTHERAPEUTICS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 026390/0193 →
CHANGE OF ADDRESS Recorded Jan 4, 2010
From: GRIFOLS, S.A.
To: GRIFOLS, S.A.
Reel/Frame 023720/0951 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 6, 2007
From: MARTORELL PENA, DANIEL; TRAVES POLO, MA DEL CARMEN; FARRE LEON, JORDI; CASTELLS PARERA, JOSEFINA
To: GRIFOLS, S.A.
Reel/Frame 019523/0368 →
Priority Claims (1)
ES 200601682 · Jun 22, 2006 · national
Continuity (1)
Related Publication 20070298406A1 · Dec 27, 2007